| Aiben(Ibandronate sodium for injection) is the newest (the third generation) bisphosphonates(BPs) and produced by the Biomedical Engineering Center of Heibei Medical University.The drug has some advantages of a high potency,a low toxicity and a easy application. Now it is becoming the main drug in prevention and treatment of bone metastases and osteoporosis.Ibandronate binds very avidly to apatite.Combining with the calcium phosphate,Ibandronate will be metablized very slowly,and its half-life will be much longer evev as long as ten years. Thus,it forms a good protective surface not only blocking bone loss but also inhibiting adhesion and invasion of tumor cells.This is the basis for the use of ibandronate in prevention of bone metastases.Ibandronate in addition, can induce apoptosis of different tumor cells,inhibite the secretion and activities of matrix metalloproteinases(MMPs),parathyroid hormone-related protein(PTHrp) and vascular endothelium growth factor(VEGF),so it can also inhibit bone resorption and metastases.Ibanedronate increases bone mineral density(BMD)significantly by increasing the secondary mineralization of bone,so it can also be used for prevention and treatment of osteoporosis.Objective Ibandronate came into the market in September,2001.There was no research papers about ibandronate reported until early 2003 in china. The earliest research article dealing with ibandronate was Aiben satety observation——clinical trial phase I and published in Chinese Journal of New Drugs and Clinical Remedies. At the same period of time, hundreds of papers about ibandronate were reported mainly dealing with pharmacokinetics,biological effects, prevention and treatment of tumor-induced bone disease and osteoporosis, mechanisms of action,treatment of mutiple myoloma,inhibition of tumor cell secretions,inducing apoptosis of tumor cells, and the combination therapies with chemotherapy, etc.And even including the prevention and treatment of heterotopic calcification induced by vitamine D and warfarin toxicity, slowing down periodontal bone destruction in periodontitis animals,inbibiting tooth movement induced by orthodontic procedures and prevention of experimentally induced arthritis ,treatment of paget`s disease. The researching methods contained open-labelled, multicenter double blind, dose-finding,interventional trials and acute,nonacute toxicity. The experimental subjects included rat,mouse,dog,pig,monkey and human beings. The experiments were carried out from short-term administration----ibandronate was given once to long-term administration----ibandronate was applied for life-long. Subjects of research included inhibition of bone resorption caused by malignancy lytic bone disease,visceral metastasis,direct antitumor effects in vivo and in vitro,comparison of the various bisphosphonates, effects on quality of life and survival time and ibandronate combining with chemotherapies. All data was substantial and convincing .Nevertheless, There was a Lack of reports about ibandronate combining with radiotherapy in the treatment of maligenant bone metastasis. Radiotheraly is one of the most important therapeutic options in the treatment of limited metastatic bone disease. In 70-90% of the osscous lesions a successful palliation can be achieved. Bisphosphonates have become another mainstay in treating metastatic bone disease. Because of their ability to reduce the osteoclastic activety of lytic bone lesions,a good pain relief an well as a high recalcitication rate can be observed. Therefore a combination of systemic bisphosphonate application with local radiotherapy may be beneficial. A local synergistic effect has also been postulated. This is why we select the topic. In order to increase the application fields of bisphosphonates, sun up the clinical effects of combination of radiotherapy and ibandronate(Aiben) in metastatic bone disease and supply a choicing remedy to doctors. Materials and methods: From 9/2001 to 5/2003, a total of 80 patients with lytic bone metastasis fr...
|
PDF Full Text Request